Park Ha Biological Technology is trading 5.3% down at $0.33 as investors continue to react to the company's recent highly dilutive capital raises.
- The stock has faced consistent downward pressure following a deeply discounted January offering and a subsequent registered direct deal involving share and warrant issuance.
- Market sentiment remains weighed down by fears of ongoing dilution and weak fundamentals, even as the broader biotechnology sector experiences a stronger performance backdrop.